$0.89
3.37%
Downside
Day's Volatility :3.91%
Upside
0.56%
52.25%
Downside
52 Weeks Volatility :73.6%
Upside
44.72%
Period | Talphera Inc | Index (Russel 2000) |
---|---|---|
3 Months | -15.91% | 0.0% |
6 Months | -14.28% | 0.0% |
1 Year | -10.82% | 0.0% |
3 Years | -96.35% | -20.2% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
What analysts predicted
Upside of 420.22%
Sell
Neutral
Buy
Talphera Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Talphera Inc | 0.33% | -14.28% | -10.82% | -96.35% | -98.19% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Talphera Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Talphera Inc | Buy | $23.6M | -98.19% | NA | 0.0% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Talphera Inc
Revenue is up for the last 2 quarters, 117.0K → 281.0K (in $), with an average increase of 58.4% per quarter
Netprofit is up for the last 2 quarters, -4.51M → -3.95M (in $), with an average increase of 14.2% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 56.3%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 149.0%
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Organization | Talphera Inc |
Employees | 15 |
CEO | Mr. Vincent J. Angotti |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.89
+0.33%
Keyarch Acquisition Corp
$0.89
+0.33%
Connexa Sports Technologies Inc
$0.89
+0.33%
Us Value Etf
$0.89
+0.33%
First Wave Biopharma Inc
$0.89
+0.33%
Global X Msci Next Emerging
$0.89
+0.33%
Fat Projects Acquisition Corp
$0.89
+0.33%
Capital Link Global Fintech
$0.89
+0.33%
Applied Uv Inc
$0.89
+0.33%